Local excision for patients with stage I anal canal squamous cell carcinoma can be curative

Sakti Chakrabarti, Zhaohui Jin, Brandon M. Huffman, Siddhartha Yadav, Rondell Graham, Dora M. Lam-Himlin, Amy Lightner, Christopher Hallemeier, Amit Mahipal

Research output: Contribution to journalArticle

Abstract

Background: Definitive concurrent chemoradiation is the current standard of care for all stage I anal canal squamous cell carcinoma. Local excision as primary treatment for selected stage I lesions has been reported in the literature but is not currently recommended by major guidelines. We herein compared the oncologic outcomes of patients with stage I anal canal squamous cell carcinoma treated with local excision alone versus chemoradiation to determine if there are any significant differences in outcomes including disease free survival, overall survival (OS) and local failure rate. Methods: A retrospective review of all patients treated for stage I anal canal squamous cell carcinoma between 1990 and 2016 was conducted. Data collected included baseline demographics, staging studies, pathology, treatment received, relapse pattern and survival. Results: A total of 57 patients were treated for stage I anal canal squamous cell carcinoma between 1990 and 2016; 13 were treated with local excision alone and 44 were treated with chemoradiation therapy. Baseline characteristics in both cohorts of patients were comparable. Median follow-up duration of the local excision and the chemoradiation cohorts were 106 and 70 months, respectively. Of the 13 patients in local excision cohort, two patients had disease recurrence, at 21 and 97 months from the diagnosis. Both patients were long term survivors with salvage treatment. In chemoradiation cohort, 1 out of 44 patients had a local recurrence at 1 year who underwent curative resection. Five-year progression free survival (PFS) of subjects in local excision cohort and chemoradiation cohort were 91% and 83%, respectively (P=0.57). Conclusions: Local excision as primary treatment may be safe and effective for a selected group of stage I anal canal squamous cell carcinoma patients.

Original languageEnglish (US)
Pages (from-to)171-178
Number of pages8
JournalJournal of Gastrointestinal Oncology
Volume10
Issue number2
DOIs
StatePublished - Apr 1 2019

Fingerprint

Anal Canal
Squamous Cell Carcinoma
Recurrence
Disease-Free Survival
Salvage Therapy
Survival
Therapeutics
Standard of Care
Survivors
Demography
Guidelines
Pathology

Keywords

  • Anal canal
  • Chemoradiation
  • Local excision
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. / Chakrabarti, Sakti; Jin, Zhaohui; Huffman, Brandon M.; Yadav, Siddhartha; Graham, Rondell; Lam-Himlin, Dora M.; Lightner, Amy; Hallemeier, Christopher; Mahipal, Amit.

In: Journal of Gastrointestinal Oncology, Vol. 10, No. 2, 01.04.2019, p. 171-178.

Research output: Contribution to journalArticle

Chakrabarti, Sakti ; Jin, Zhaohui ; Huffman, Brandon M. ; Yadav, Siddhartha ; Graham, Rondell ; Lam-Himlin, Dora M. ; Lightner, Amy ; Hallemeier, Christopher ; Mahipal, Amit. / Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. In: Journal of Gastrointestinal Oncology. 2019 ; Vol. 10, No. 2. pp. 171-178.
@article{241afb07b77f4eecbf984ec34b1cdcfa,
title = "Local excision for patients with stage I anal canal squamous cell carcinoma can be curative",
abstract = "Background: Definitive concurrent chemoradiation is the current standard of care for all stage I anal canal squamous cell carcinoma. Local excision as primary treatment for selected stage I lesions has been reported in the literature but is not currently recommended by major guidelines. We herein compared the oncologic outcomes of patients with stage I anal canal squamous cell carcinoma treated with local excision alone versus chemoradiation to determine if there are any significant differences in outcomes including disease free survival, overall survival (OS) and local failure rate. Methods: A retrospective review of all patients treated for stage I anal canal squamous cell carcinoma between 1990 and 2016 was conducted. Data collected included baseline demographics, staging studies, pathology, treatment received, relapse pattern and survival. Results: A total of 57 patients were treated for stage I anal canal squamous cell carcinoma between 1990 and 2016; 13 were treated with local excision alone and 44 were treated with chemoradiation therapy. Baseline characteristics in both cohorts of patients were comparable. Median follow-up duration of the local excision and the chemoradiation cohorts were 106 and 70 months, respectively. Of the 13 patients in local excision cohort, two patients had disease recurrence, at 21 and 97 months from the diagnosis. Both patients were long term survivors with salvage treatment. In chemoradiation cohort, 1 out of 44 patients had a local recurrence at 1 year who underwent curative resection. Five-year progression free survival (PFS) of subjects in local excision cohort and chemoradiation cohort were 91{\%} and 83{\%}, respectively (P=0.57). Conclusions: Local excision as primary treatment may be safe and effective for a selected group of stage I anal canal squamous cell carcinoma patients.",
keywords = "Anal canal, Chemoradiation, Local excision, Squamous cell carcinoma",
author = "Sakti Chakrabarti and Zhaohui Jin and Huffman, {Brandon M.} and Siddhartha Yadav and Rondell Graham and Lam-Himlin, {Dora M.} and Amy Lightner and Christopher Hallemeier and Amit Mahipal",
year = "2019",
month = "4",
day = "1",
doi = "10.21037/jgo.2018.12.12",
language = "English (US)",
volume = "10",
pages = "171--178",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "2",

}

TY - JOUR

T1 - Local excision for patients with stage I anal canal squamous cell carcinoma can be curative

AU - Chakrabarti, Sakti

AU - Jin, Zhaohui

AU - Huffman, Brandon M.

AU - Yadav, Siddhartha

AU - Graham, Rondell

AU - Lam-Himlin, Dora M.

AU - Lightner, Amy

AU - Hallemeier, Christopher

AU - Mahipal, Amit

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Definitive concurrent chemoradiation is the current standard of care for all stage I anal canal squamous cell carcinoma. Local excision as primary treatment for selected stage I lesions has been reported in the literature but is not currently recommended by major guidelines. We herein compared the oncologic outcomes of patients with stage I anal canal squamous cell carcinoma treated with local excision alone versus chemoradiation to determine if there are any significant differences in outcomes including disease free survival, overall survival (OS) and local failure rate. Methods: A retrospective review of all patients treated for stage I anal canal squamous cell carcinoma between 1990 and 2016 was conducted. Data collected included baseline demographics, staging studies, pathology, treatment received, relapse pattern and survival. Results: A total of 57 patients were treated for stage I anal canal squamous cell carcinoma between 1990 and 2016; 13 were treated with local excision alone and 44 were treated with chemoradiation therapy. Baseline characteristics in both cohorts of patients were comparable. Median follow-up duration of the local excision and the chemoradiation cohorts were 106 and 70 months, respectively. Of the 13 patients in local excision cohort, two patients had disease recurrence, at 21 and 97 months from the diagnosis. Both patients were long term survivors with salvage treatment. In chemoradiation cohort, 1 out of 44 patients had a local recurrence at 1 year who underwent curative resection. Five-year progression free survival (PFS) of subjects in local excision cohort and chemoradiation cohort were 91% and 83%, respectively (P=0.57). Conclusions: Local excision as primary treatment may be safe and effective for a selected group of stage I anal canal squamous cell carcinoma patients.

AB - Background: Definitive concurrent chemoradiation is the current standard of care for all stage I anal canal squamous cell carcinoma. Local excision as primary treatment for selected stage I lesions has been reported in the literature but is not currently recommended by major guidelines. We herein compared the oncologic outcomes of patients with stage I anal canal squamous cell carcinoma treated with local excision alone versus chemoradiation to determine if there are any significant differences in outcomes including disease free survival, overall survival (OS) and local failure rate. Methods: A retrospective review of all patients treated for stage I anal canal squamous cell carcinoma between 1990 and 2016 was conducted. Data collected included baseline demographics, staging studies, pathology, treatment received, relapse pattern and survival. Results: A total of 57 patients were treated for stage I anal canal squamous cell carcinoma between 1990 and 2016; 13 were treated with local excision alone and 44 were treated with chemoradiation therapy. Baseline characteristics in both cohorts of patients were comparable. Median follow-up duration of the local excision and the chemoradiation cohorts were 106 and 70 months, respectively. Of the 13 patients in local excision cohort, two patients had disease recurrence, at 21 and 97 months from the diagnosis. Both patients were long term survivors with salvage treatment. In chemoradiation cohort, 1 out of 44 patients had a local recurrence at 1 year who underwent curative resection. Five-year progression free survival (PFS) of subjects in local excision cohort and chemoradiation cohort were 91% and 83%, respectively (P=0.57). Conclusions: Local excision as primary treatment may be safe and effective for a selected group of stage I anal canal squamous cell carcinoma patients.

KW - Anal canal

KW - Chemoradiation

KW - Local excision

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85065103754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065103754&partnerID=8YFLogxK

U2 - 10.21037/jgo.2018.12.12

DO - 10.21037/jgo.2018.12.12

M3 - Article

AN - SCOPUS:85065103754

VL - 10

SP - 171

EP - 178

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 2

ER -